NGeneBio Co., Ltd. (KOSDAQ:354200)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Medical Labs & Research	4.35B	11.02B	7.16B
Medical Labs & Research Growth	-60.51%	53.81%	-
Total	4.35B	11.02B	7.16B
Total Growth	-60.51%	53.81%	-

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
South Korea	4.12B	9.80B	5.97B
South Korea Growth	-58.01%	64.35%	-
Overseas	233.96M	1.21B	1.20B
Overseas Growth	-80.71%	1.28%	-
Total	4.35B	11.02B	7.16B
Total Growth	-60.51%	53.81%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 20, 2026

Data Sources Report a data error